Dapagliflozin attenuates AKI to CKD transition in diabetes by activating SIRT3/PGC1-α signaling and alleviating aberrant metabolic reprogrammingHuimin Li, Zhixia Song, Hongchu Zha et al.|Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease|2024Cited by 13